Keros Therapeutics Inc (NASDAQ:KROS) price on Thursday, February 06, rose 3.46% above its previous day’s close as an upside momentum from buyers pushed the stock’s value to $11.52.
A look at the stock’s price movement, the close in the last trading session was $11.13, moving within a range at $11.01 and $12.05. The beta value (5-Year monthly) was 1.236. Turning to its 52-week performance, $73.00 and $9.77 were the 52-week high and 52-week low respectively. Overall, KROS moved -26.37% over the past month.
Keros Therapeutics Inc’s market cap currently stands at around $466.45 million, with investors looking forward to this quarter’s earnings report slated for in March.
The average forecast suggests up to a 25,996.63% growth in sales growth compared to quarterly growth in the same period last fiscal year. Wall Street analysts have also projected the company’s year-on-year revenue to grow to 32.05M, representing a 21,125.47% jump on that reported in the last financial year.
Turning to the stock’s technical picture we see that short term indicators suggest on average that KROS is a 100% Sell. On the other hand, the stock is on average a 100% Sell as suggested by medium term indicators while long term indicators are putting the stock in 100% Sell category.
3 analyst(s) have given their forecast ratings for the stock on a scale of 1.00-5.00 for a strong buy to strong sell recommendation. A total of 0 analyst(s) rate the stock as a Hold, 3 recommend KROS as a Buy and 0 give it an Overweight rating. Meanwhile, 0 analyst(s) rate the stock as Underweight and 0 say it is a Sell. As such, the average rating for the stock is Buy which could provide an opportunity for investors keen on increasing their holdings of the company’s stock.
KROS’s current price about -2.09% and -56.80% off the 20-day and 50-day simple moving averages respectively. The Relative Strength Index (RSI, 14) currently prints 28.50, while 7-day volatility ratio is 4.53% and 6.07% in the 30-day chart. Further, Keros Therapeutics Inc (KROS) has a beta value of 1.40, and an average true range (ATR) of 1.20. Analysts have given the company’s stock an average 52-week price target of $100, forecast between a low of $96 and high of $107. Looking at the price targets, the low is -733.33% off current price level while to achieve the yearly target high, price needs to move -828.82%. Nonetheless, investors will most likely welcome a -768.06% jump to $100 which is the analysts’ median price.
If we refocus on Keros Therapeutics Inc (NASDAQ:KROS), historical trading data shows that trading volumes averaged 1.14 over the past 10 days and 1.51 million over the past 3 months. The company’s latest data on shares outstanding shows there are 39.26 million shares.
The 18.87% of Keros Therapeutics Inc’s shares are in the hands of company insiders while institutional holders own 83.26% of the company’s shares. Also important is the data on short interest which shows that short shares stood at 4.02 million on 2025-01-15, giving us a short ratio of 2.14. The data shows that as of 2025-01-15 short interest in Keros Therapeutics Inc (KROS) stood at 1351.0 of shares outstanding, with shares short rising to 3.03 million registered in 2024-12-13. Current price change has pushed the stock -27.26% YTD, which shows the potential for further growth is there. It is this reason that could see investor optimism for the KROS stock continues to rise going into the next quarter.
